New pharmacological developments in the treatment of hepatocellular cancer

Niraj J. Gusani, Yixing Jiang, Eric T. Kimchi, Kevin F. Staveley-O'Carroll, Hua Cheng, Jaffer A. Ajani

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm and fourth leading cause of cancer death worldwide. The survival for patients with advanced HCC is extremely poor. This is largely attributed to the lack of effective screening methods, advanced stage at presentation, limited utility of surgical intervention and ineffective medical therapy. Over the past 30 years, many conventional cytotoxic agents have been tested and have failed to confer a survival benefit. Recently, sorafenib, a multi-tyrosine kinase inhibitor, was approved by the US FDA as first-line therapy in HCC as the first agent demonstrating survival benefit in this disease. Although the survival benefit demonstrated by sorafenib is moderate, molecular targeted therapy has brought new hope in the management of HCC.

Original languageEnglish (US)
Pages (from-to)2533-2540
Number of pages8
JournalDrugs
Volume69
Issue number18
DOIs
StatePublished - Dec 17 2009

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Pharmacology
Survival
Molecular Targeted Therapy
Cytotoxins
Therapeutics
Protein-Tyrosine Kinases
Cause of Death
Neoplasms
sorafenib

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Gusani, N. J., Jiang, Y., Kimchi, E. T., Staveley-O'Carroll, K. F., Cheng, H., & Ajani, J. A. (2009). New pharmacological developments in the treatment of hepatocellular cancer. Drugs, 69(18), 2533-2540. https://doi.org/10.2165/11530870-000000000-00000
Gusani, Niraj J. ; Jiang, Yixing ; Kimchi, Eric T. ; Staveley-O'Carroll, Kevin F. ; Cheng, Hua ; Ajani, Jaffer A. / New pharmacological developments in the treatment of hepatocellular cancer. In: Drugs. 2009 ; Vol. 69, No. 18. pp. 2533-2540.
@article{aad4f84341af46f48f4e23227c9f656d,
title = "New pharmacological developments in the treatment of hepatocellular cancer",
abstract = "Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm and fourth leading cause of cancer death worldwide. The survival for patients with advanced HCC is extremely poor. This is largely attributed to the lack of effective screening methods, advanced stage at presentation, limited utility of surgical intervention and ineffective medical therapy. Over the past 30 years, many conventional cytotoxic agents have been tested and have failed to confer a survival benefit. Recently, sorafenib, a multi-tyrosine kinase inhibitor, was approved by the US FDA as first-line therapy in HCC as the first agent demonstrating survival benefit in this disease. Although the survival benefit demonstrated by sorafenib is moderate, molecular targeted therapy has brought new hope in the management of HCC.",
author = "Gusani, {Niraj J.} and Yixing Jiang and Kimchi, {Eric T.} and Staveley-O'Carroll, {Kevin F.} and Hua Cheng and Ajani, {Jaffer A.}",
year = "2009",
month = "12",
day = "17",
doi = "10.2165/11530870-000000000-00000",
language = "English (US)",
volume = "69",
pages = "2533--2540",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "18",

}

Gusani, NJ, Jiang, Y, Kimchi, ET, Staveley-O'Carroll, KF, Cheng, H & Ajani, JA 2009, 'New pharmacological developments in the treatment of hepatocellular cancer', Drugs, vol. 69, no. 18, pp. 2533-2540. https://doi.org/10.2165/11530870-000000000-00000

New pharmacological developments in the treatment of hepatocellular cancer. / Gusani, Niraj J.; Jiang, Yixing; Kimchi, Eric T.; Staveley-O'Carroll, Kevin F.; Cheng, Hua; Ajani, Jaffer A.

In: Drugs, Vol. 69, No. 18, 17.12.2009, p. 2533-2540.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New pharmacological developments in the treatment of hepatocellular cancer

AU - Gusani, Niraj J.

AU - Jiang, Yixing

AU - Kimchi, Eric T.

AU - Staveley-O'Carroll, Kevin F.

AU - Cheng, Hua

AU - Ajani, Jaffer A.

PY - 2009/12/17

Y1 - 2009/12/17

N2 - Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm and fourth leading cause of cancer death worldwide. The survival for patients with advanced HCC is extremely poor. This is largely attributed to the lack of effective screening methods, advanced stage at presentation, limited utility of surgical intervention and ineffective medical therapy. Over the past 30 years, many conventional cytotoxic agents have been tested and have failed to confer a survival benefit. Recently, sorafenib, a multi-tyrosine kinase inhibitor, was approved by the US FDA as first-line therapy in HCC as the first agent demonstrating survival benefit in this disease. Although the survival benefit demonstrated by sorafenib is moderate, molecular targeted therapy has brought new hope in the management of HCC.

AB - Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm and fourth leading cause of cancer death worldwide. The survival for patients with advanced HCC is extremely poor. This is largely attributed to the lack of effective screening methods, advanced stage at presentation, limited utility of surgical intervention and ineffective medical therapy. Over the past 30 years, many conventional cytotoxic agents have been tested and have failed to confer a survival benefit. Recently, sorafenib, a multi-tyrosine kinase inhibitor, was approved by the US FDA as first-line therapy in HCC as the first agent demonstrating survival benefit in this disease. Although the survival benefit demonstrated by sorafenib is moderate, molecular targeted therapy has brought new hope in the management of HCC.

UR - http://www.scopus.com/inward/record.url?scp=71849115391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849115391&partnerID=8YFLogxK

U2 - 10.2165/11530870-000000000-00000

DO - 10.2165/11530870-000000000-00000

M3 - Review article

C2 - 19943706

AN - SCOPUS:71849115391

VL - 69

SP - 2533

EP - 2540

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 18

ER -

Gusani NJ, Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. New pharmacological developments in the treatment of hepatocellular cancer. Drugs. 2009 Dec 17;69(18):2533-2540. https://doi.org/10.2165/11530870-000000000-00000